-
公开(公告)号：US09884817B2
公开(公告)日：2018-02-06
申请号：US15317532
申请日：2015-06-11
申请人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia Ou , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
发明人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia Ou , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
IPC分类号： C07D207/09 , A61K47/48 , C07D403/12 , C07D401/12 , C07D413/12 , C07D403/14 , C07K16/32
CPC分类号： C07D207/09 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , C07D401/12 , C07D403/12 , C07D403/14 , C07D413/12 , C07K5/0205 , C07K16/32
摘要： Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US20170121282A1
公开(公告)日：2017-05-04
申请号：US15317532
申请日：2015-06-11
申请人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia OU , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
发明人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia OU , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
IPC分类号： C07D207/09 , C07K16/32 , C07D413/12 , C07D403/14 , C07D403/12 , C07D401/12
CPC分类号： C07D207/09 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , C07D401/12 , C07D403/12 , C07D403/14 , C07D413/12 , C07K5/0205 , C07K16/32
摘要： Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US09988420B2
公开(公告)日：2018-06-05
申请号：US15104727
申请日：2014-12-17
申请人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia Ou , Tetsuo Uno , Yongqin Wan , Xing Wang , Yunho Jin
发明人： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia Ou , Tetsuo Uno , Yongqin Wan , Xing Wang , Yunho Jin
CPC分类号： C07K5/0205 , A61K47/6817 , A61K47/6851 , C07K7/02 , C07K16/32
摘要： Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US10973826B2
公开(公告)日：2021-04-13
申请号：US15333285
申请日：2016-10-25
申请人： Alex Cortez , Bernhard Hubert Geierstanger , Timothy Z. Hoffman , Shailaja Kasibhatla , Tetsuo Uno , Xing Wang , Tom Yao-Hsiang Wu
发明人： Alex Cortez , Bernhard Hubert Geierstanger , Timothy Z. Hoffman , Shailaja Kasibhatla , Tetsuo Uno , Xing Wang , Tom Yao-Hsiang Wu
摘要： Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
-
公开(公告)号：US09580426B2
公开(公告)日：2017-02-28
申请号：US13857939
申请日：2013-04-05
申请人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
发明人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
IPC分类号： C07D473/34 , A61K38/00 , C07D487/04 , C12N5/0789 , C07D473/16 , C07D495/04
CPC分类号： A61K35/28 , A61K9/0019 , A61K31/52 , A61K38/00 , A61K2035/124 , C07D473/16 , C07D473/34 , C07D487/04 , C07D495/04 , C12N5/0647 , C12N2501/38 , C12N2501/60
摘要： The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
摘要翻译： 本发明涉及用于扩增用于移植的CD34 +细胞数量的化合物和组合物。 本发明还涉及包含扩大的造血干细胞（HSCs）的细胞群及其在自体或同种异体移植中用于治疗遗传性免疫缺陷和自身免疫性疾病和多种造血障碍的患者的细胞群，以重建造血细胞谱系和免疫系统防御。
-
6.发明授权N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors 有权N-（吡啶-2-基）磺酰胺及其组合物作为蛋白激酶抑制剂公开(公告)号：US09181238B2
公开(公告)日：2015-11-10
申请号：US13577209
申请日：2011-02-04
申请人： Shifeng Pan , John E. Tellew , Yongqin Wan , Yongping Xie , Xing Wang , Xia Wang , Shenlin Huang , Zuosheng Liu , Qiong Zhang
发明人： Shifeng Pan , John E. Tellew , Yongqin Wan , Yongping Xie , Xing Wang , Xia Wang , Shenlin Huang , Zuosheng Liu , Qiong Zhang
IPC分类号： A61K31/444 , C07D213/75 , C07D471/04 , C07D401/14 , A61K31/506 , A61K31/519 , A61K45/06
CPC分类号： C07D471/04 , A61K31/444 , A61K31/506 , A61K31/519 , A61K45/06 , C07D401/14
摘要： The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
摘要翻译： 本发明提供了一类新颖的式（I）化合物（其中A，Y，R 2，R 3，R 4和R 5在本发明概述中定义），包含这些化合物的药物组合物和使用这些化合物治疗或 预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及B-Raf异常活化的疾病或病症。
-
公开(公告)号：US20100183564A1
公开(公告)日：2010-07-22
申请号：US12608946
申请日：2009-10-29
申请人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
发明人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
IPC分类号： A61K35/28 , C07D473/34 , A61K31/52 , A61P35/02 , A61P35/00 , A61P7/06 , A61P37/00 , C12N5/0789 , C12N5/078
CPC分类号： A61K35/28 , A61K9/0019 , A61K31/52 , A61K38/00 , A61K2035/124 , C07D473/16 , C07D473/34 , C07D487/04 , C07D495/04 , C12N5/0647 , C12N2501/38 , C12N2501/60
摘要： The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
摘要翻译： 本发明涉及用于扩增用于移植的CD34 +细胞数量的化合物和组合物。 本发明还涉及包含扩大的造血干细胞（HSCs）的细胞群及其在自体或同种异体移植中用于治疗遗传性免疫缺陷和自身免疫性疾病和多种造血障碍的患者的细胞群，以重建造血细胞谱系和免疫系统防御。
-
公开(公告)号：US08927281B2
公开(公告)日：2015-01-06
申请号：US12608946
申请日：2009-10-29
申请人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
发明人： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
IPC分类号： C12N5/00 , C12N5/0789 , C07D487/04 , C07D473/34 , C07D473/16 , A61K38/00 , C07D495/04
CPC分类号： A61K35/28 , A61K9/0019 , A61K31/52 , A61K38/00 , A61K2035/124 , C07D473/16 , C07D473/34 , C07D487/04 , C07D495/04 , C12N5/0647 , C12N2501/38 , C12N2501/60
摘要： The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
摘要翻译： 本发明涉及用于扩增用于移植的CD34 +细胞数量的化合物和组合物。 本发明还涉及包含扩大的造血干细胞（HSCs）的细胞群及其在自体或同种异体移植中用于治疗遗传性免疫缺陷和自身免疫性疾病和多种造血障碍的患者的细胞群，以重建造血细胞谱系和免疫系统防御。
-
公开(公告)号：US20130143899A1
公开(公告)日：2013-06-06
申请号：US13577209
申请日：2011-02-04
申请人： Shifeng Pan , John E. Tellew , Yongqin Wan , Yongping Xie , Xing Wang , Xia Wang , Shenlin Huang , Zuosheng Liu , Qiong Zhang
发明人： Shifeng Pan , John E. Tellew , Yongqin Wan , Yongping Xie , Xing Wang , Xia Wang , Shenlin Huang , Zuosheng Liu , Qiong Zhang
IPC分类号： C07D471/04 , A61K45/06 , A61K31/444 , A61K31/519 , C07D401/14 , A61K31/506
CPC分类号： C07D471/04 , A61K31/444 , A61K31/506 , A61K31/519 , A61K45/06 , C07D401/14
摘要： The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
摘要翻译： 本发明提供了一类新颖的式（I）化合物（其中A，Y，R 2，R 3，R 4和R 5在本发明概述中定义），包含这些化合物的药物组合物和使用这些化合物治疗或 预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及B-Raf异常活化的疾病或病症。
-
公开(公告)号：US20110306625A1
公开(公告)日：2011-12-15
申请号：US12870130
申请日：2010-08-27
申请人： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
发明人： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC分类号： A61K31/506 , A61P25/24 , A61P1/08 , C07D401/04 , A61P35/00
CPC分类号： C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及B-Raf异常激活的疾病或病症。
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.047 秒)
